Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia☆
-
Add time:08/19/2019 Source:sciencedirect.com
BackgroundPatients with high-risk gestational trophoblastic neoplasia (GTN) need multi-agent chemotherapy to be cured. The most common regimen is etoposide (E), methotrexate (M) and actinomycin D (A), alternating weekly with cyclophosphamide (C) plus vincristine (O) (EMA/CO). Cisplatin (P) is a very active drug, but it is usually restricted to second-line therapies. Herein, we report the results of a cisplatin-based therapy: APE (actinomycin D, cisplatin, and etoposide).
We also recommend Trading Suppliers and Manufacturers of actinomycin K (cas 11011-00-0). Pls Click Website Link as below: cas 11011-00-0 suppliers
Prev:Coordination ability of silver(I) with antimycins and actinomycins – Properties of the T-shaped chromophores
Next:Study on growth and Ascomycin (cas 11011-38-4) production by Streptomyces hygroscopicus subsp. Ascomyceticus) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Coordination ability of silver(I) with antimycins and actinomycins – Properties of the T-shaped chromophores08/18/2019
- Structural aspects of the interaction of anticancer drug Actinomycin-D to the GC rich region of hmgb1 gene08/17/2019
- Purification and identification of an actinomycin D analogue from actinomycetes associated with Ganoderma applanatum via magnetic molecularly imprinted polymers and tandem mass spectrometry08/16/2019
- Modeling improved production of the chemotherapeutic polypeptide actinomycin D by a novel Streptomyces sp. strain from a Saharan soil08/15/2019
- Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?08/14/2019
-
Health and Chemical more >